Agitated patients who present a danger to themselves or emergency medical services providers may require chemical restraints.
Background
Minimising unnecessary delays between patient contact and transport from the scene to a receiving hospital is a key component of high functioning emergency medical services (EMS) systems (1) . As the medical capabilities of pre-hospital professionals continue to grow in both breadth and depth, there is a constant struggle to ensure an appropriate balance between the provision of medical care and the need to minimise delays on scene. In agitated patients, when there is danger to the EMS crew, the current recommendations state that it is 'medically appropriate for EMS personnel to delay patient care until they determine the scene is safe (2)'.
Agitated patients present unique challenges, which can complicate medical care and delay EMS transport to a hospital. Violent patients are an occupational hazard for EMS professionals (3, 4) who frequently encounter patients with decompensated psychiatric illness and drug or alcohol intoxication, both of which have been linked to provider assault (5) . In one study of EMS occupational fatalities, 11% of deaths were due to assaults and were classified as homicides (6) . Despite these dangers, violent and agitated patients require a detailed medical assessment as behavioural emergencies can mask serious underlying medical and traumatic pathologies.
Restraints are often employed by EMS professionals to help control violent and agitated patients, to minimise risk to the providers and to improve the ability of the providers to perform a physical exam. Unfortunately, physical restraints have been associated with in-custody deaths. These have been theorised to be caused by impaired ventilation (positional asphyxia) (7), metabolic acidosis (8) and excited delirium (ExDS) (9) . ExDS in particular, has been linked to mortality from a catecholamine surge that may be worsened as patients struggle against physical restraints (10) . Chemical restraints decrease agitation in patients who are physically restrained (11) . The pharmacologic agents most commonly used for chemical restraint include benzodiazepines, neuroleptics and more recently, ketamine (12) .
In our EMS system, ketamine became an option for pre-hospital chemical restraint in April of 2011. Prior to this, haloperidol combined with a benzodiazepine or diphenhydramine, was the only option available. Ketamine has a rapid onset of action of 3.3 minutes using a 5 mg/kg intramuscular dose (13) . Despite this rapid onset we hypothesised that the inability of a patient who is in a dissociated state to ambulate, the need for more detailed monitoring of the patient's airway, breathing, and circulation and the occasional need for intervention to address issues such as hypoxia or hyper-salivation may prolong the on-scene time. By consensus the authors identified differences in on-scene time of ≥5 minutes as clinically significant. The primary aim of this study was to investigate whether pre-hospital cases where ketamine was used for chemical restraint had clinically significant increases in on-scene times (≥5 minutes) compared to those in which haloperidol based regimens were chosen.
Methods

Setting
This was a retrospective study of electronic pre-hospital care reports (E-PCRs) from an urban, fire-based, municipal, single tier EMS system. In the authors' city of St Paul, Minnesota, U.S.A. of 285,000 people, there are approximately 35,000 911 calls per year answered by paramedic staffed ambulances out of 12 fixed locations. Additional first response capabilities are provided by units out of an additional three stations. The city of St Paul has one Level 1 trauma centre and two additional tertiary care hospitals clustered in the downtown area.
Population
Historically, paramedics in our EMS system have had the option to treat severely agitated or violent patients with both physical and chemical restraints. Prior to April 2011, the pharmacologic agents used for chemical restraint were limited to intramuscular haloperidol (5 mg) combined with a benzodiazepine (lorazepam 2 mg or midazolam 2 mg) and diphenhydramine 50 mg (ie. 'B52'). In April 2011, ketamine 5 mg/kg intramuscular was authorised for patients who were severely agitated, actively violent or in ExDS.
Data collection
Institutional review board approval was obtained prior to data collection. The E-PCR database was queried to retrospectively identify patients who were administered intramuscular ketamine or haloperidol. The only authorised indication for these agents on standing order was for chemical restraint. Co-administration of benzodiazepines or diphenhydramine was also recorded. The E-PCR documented times included on-scene, patient contact and left scene. On-scene time was calculated as the difference between patient contact time and left scene time.
Data analysis
Based on quality improvement data review, the average on-scene time for patients treated with haloperidol was 19.8 minutes. To power the study to detect clinically and statistically meaningful differences of ≥5 minutes in on-scene time between groups, a total of 110 cases were needed (55 ketamine, 55 haloperidol). Five minutes was chosen as it was felt to represent a clinically significant difference in on-scene time. Differences in on-scene time of 0-4:59 minutes, even if statistically significant, were felt by the authors to have a lower probability of resulting in meaningful differences in clinical outcomes in this patient population. Data were extracted from the E-PCR into Microsoft Excel software (Microsoft Corp., Redmond, WA). Demographic characteristics (age, gender) were compared between groups. Student t-test was used to compare average on-scene time, with a p-value of <0.05 considered statistically significant.
Ethics
This study was approved by the Institutional Review Board (IRB) which reviews studies involving human subjects at our institution.
Results
110 patients administered chemical restraint were included in our analysis (haloperidol 55, ketamine 55). Co-administration of benzodiazepines and diphenhydramine was common in the haloperidol cohort while ketamine was given exclusively as monotherapy (Figure 1 Haloperidol Monotherapy N=6
Discussion
In this study there was no clinically significant difference in onscene time between patients administered haloperidol based sedation than those given ketamine. This study was powered to detect a difference in on-scene time of ≥5 minutes which, based on the authors' experience and clinical practice, was believed to represent a discrepancy which was most likely to impact clinical care and patient outcomes. Fractile times are widely used by high performing EMS systems to demonstrate response time reliability. Unlike average times which may be heavily impacted by a relatively small number of outlying data points, fractile times report the percentage of runs which occur within pre-defined time periods. This reporting scheme presents a more accurate representation of the consistency of an agencies performance. In this study, both the average and fractile on-scene times were not significantly different between cohorts.
On-scene times consist of gaining access to the patient, assessment, treatment and extrication. Patients who require chemical restraints present unique challenges that may prolong the on-scene time relative to cooperative ill or injured patients. EMS runs with uncooperative patients have a statistically significant longer total on-scene time than equivalent runs with cooperative patients (14) . Prolonged times for patient assessment and extrication to the ambulance were identified as responsible for the delay. Gaining access to the patient may be delayed by the need for law enforcement to gain control and custody prior to clearing EMS to approach the patient. Staging for scene security was shown to add an average of 4.5 minutes to ambulance response times (15) . Due to the inability to accurately examine a violent patient prior to chemical restraint, pathology requiring emergent stabilisation may become apparent only after the patient is sedate. Head trauma, drug or alcohol withdrawal, metabolic derangements, toxic ingestion and ExDS are a few of the many conditions that frequently have a behavioural component to their presentation. 
Figure 2
In one study of violent patients encountered by EMS 9% were found to be hypoglycemic (16) . Another study demonstrated that 2% of patients admitted on an emergency basis to an inpatient psychiatric ward had a medical cause of their symptoms and an additional 3.5% had a medical cause exacerbating a comorbid psychiatric condition (17) . Inadequate physical exam has been identified as a major contributor to the misdiagnosis of a medical emergency as a psychiatric condition (18); however, performing an accurate, thorough or complete physical exam in a violent patient is impractical, unsafe and typically impossible.
In patients who require chemical restraint, available options for pre-hospital providers include antipsychotics, benzodiazepines and ketamine. Each of these three pharmacologic classes present risks and benefits. Haloperidol has been associated with the neuroleptic malignant syndrome (19) and QTc prolongation leading to torsades de pointes (20) . However, it also has a long record of safe clinical use in undifferentiated agitation and is in widespread use in EMS (21) (22) (23) (24) . Benzodiazepines are effective agents for sedation yet and there is literature to suggest that they are less effective as monotherapy than antipsychotics when used to sedate patients with undifferentiated agitation (25) . Midazolam has been associated with increased need for active airway management compared to droperidol (26) . Martel et al reported an intubation rate of 40% (12/30) for patients receiving midazolam by EMS providers for chemical restraint (27) . When lorazepam was combined with haloperidol their co-administration was found to decrease the time to onset of sedation relative to monotherapy with either agent alone (28) . However, this same study also demonstrated that patients frequently required multiple doses of study drug to achieve adequate sedation. Adding diphenhydramine to a haloperidol sedation regimen was observed in 38/55 (69%) of our patients. This is optional in our EMS guidelines and we were unable to determine from this data set if it was given for prophylaxis or treatment of extrapyramidal symptoms.
Ketamine has been used successfully for acute control of violent and combative patients in the pre-hospital environment (29) . For patients in ExDS, ketamine has been proposed as an attractive agent due to its rapid onset of action, propensity to maintain respiratory drive and lack of hypotensive effect (30) . It has been shown to be effective for pre-hospital sedation in this patient population (31) . Despite a propensity to maintain airway reflexes and respiratory drive, patients sedated with ketamine by EMS have required intubation for laryngospasm and respiratory failure (32) . Ketamine also has an onset of action which has been reported to be <5 minutes when given intramuscular (IM) in the pre-hospital environment (14) . The neutral effect which ketamine based chemical restraint had on EMS on-scene times relative to a haloperidol based approach fills a knowledge gap regarding the pre-hospital use of ketamine. Further studies aimed at defining the efficacy and adverse event profile of prehospital ketamine for chemical restraint are warranted.
Limitations of this study
This study was a chart-based retrospective analysis. Although the study was conducted in a large metropolitan area, it was limited only to patients treated by a single EMS service with a short transport time to definitive care. This may affect the generalisability of our results to rural populations. The power analysis was designed to detect a ≥5 minute difference between groups. The authors felt this was a clinically significant time period which would be useful to EMS medical directors as they weigh the impact which the two sedation regimens have on patient care and ambulance operations. It is possible that if this study had a larger sample size a statistically significant difference between cohorts would become apparent for differences in on-scene time of <5 minutes; however, the clinical significance of differences in on-scene times of between 0-4:59 minutes in this patient population is questionable.
This study was focused on the impact which each of the sedation regimens had on on-scene time. It did not examine the efficacy or rates of adverse events in each group. These important questions should be addressed in distinct studies.
Finally, data was self-reported into the E-PCRs by on-scene EMS providers and there was no way to externally validate the accuracy of the documented variables.
Conclusion
In this urban EMS system, the use of pre-hospital ketamine for chemical restraint was not associated with a clinically significant (≥5 minute) difference in on-scene time compared to haloperidol based sedation.
